Loop Diuretics in Severe Bronchopulmonary Dysplasia
A marked variation in loop diuretic use for infants developing severe BPD exists among US children's hospitals, without an observed difference in mortality or age at discharge.
Summary
Loop Diuretics in Severe Bronchopulmonary Dysplasia
Cumulative Use and Associations with Mortality and Age at Discharge
[Posted 23/Apr/2021]
AUDIENCE: Psychiatry, Family Medicine
KEY FINDINGS: A marked variation in loop diuretic use for infants developing severe BPD exists among US children's hospitals, without an observed difference in mortality or age at discharge. More research is needed to provide evidence-based guidance for this common exposure.
BACKGROUND: To measure between-center variation in loop diuretic use in infants developing severe bronchopulmonary dysplasia (BPD) in US children's hospitals, and to compare mortality and age at discharge between infants from low-use centers and infants from high-use centers.
DETAILS: A retrospective cohort study of preterm infants at 32 weeks of gestational age with severe BPD was performed. The primary outcome was cumulative loop diuretic use, defined as the proportion of days with exposure between admission and discharge. Infant characteristics associated with loop diuretic use at P .10 were included in multivariable models to adjust for center differences in case mix. Hospitals were ranked from lowest to highest in adjusted use and dichotomized into low-use centers and high-use centers. Then mortality and postmenstrual age at discharge between the groups through multivariable analyses were compared. 3252 subjects from 43 centers were identified. Significant variation between centers remained despite adjustment for infant characteristics, with use present in an adjusted mean range of 7.3% to 49.4% of days (P .0001). Mortality did not differ significantly between the 2 groups (aOR, 0.98; 95% CI, 0.62-1.53; P = .92), nor did postmenstrual age at discharge (marginal mean, 47.3 weeks [95% CI, 46.8-47.9 weeks] in the low-use group vs 47.4 weeks [95% CI, 46.9-47.9 weeks] in the high-use group; P = .96).
Our Most Popular Resources
Copyright © 2021 Elsevier Inc. All rights reserved.
Source: Bamat, N. A., Nelin, T. D., Eichenwald, E. C., et al. (2021). Loop Diuretics in Severe Bronchopulmonary Dysplasia: Cumulative Use and Associations with Mortality and Age at Discharge. J Pediatr.. 2021; 231: 43-49. E3. Published: April 1, 2021. DOI: 10.1016/j.jpeds.2020.10.073
Ensitrelvir for Covid-19 Postexposure Prophylaxis in Household Contacts
Early initiation of a 5-day oral ensitrelvir regimen within 72 hours after symptom onset in an index patient significantly reduced the risk of developing Covid-19 among household contacts while maintaining a safety profile comparable to placebo. Clinical benefit was observed across major patient subgroups, including individuals at increased risk for severe disease, and treatment was associated with reduced household transmission. These findings support ensitrelvir as an effective postexposure prophylactic option for household contacts and suggest potential utility in other high-risk exposure settings where rapid outbreak control is needed.
Our Most Popular Resources
Pharmacogenomic-Informed Antidepressant Prescribing in Australian Primary Care
In this pragmatic double-blind randomized controlled trial conducted in Australian primary care, pharmacogenomic-informed antidepressant prescribing did not improve depressive symptoms compared with prescribing guided by national therapeutic guidelines. Clinical outcomes, medication tolerability, adherence, and quality of life were similar between groups, while cost-effectiveness analyses did not support routine implementation of pharmacogenomic testing in this setting. These findings suggest that broad pharmacogenomic-guided antidepressant prescribing in general practice does not provide additional clinical benefit over guideline-based management, although targeted evaluation in carefully selected patient populations may warrant further investigation.
Our Most Popular Resources
Is Cyanoacrylate Fixation Safe for Neonatal IV Access? A Quality Improvement Evaluation of Cyanoacrylate Adhesive Securement for Short Peripheral Catheters
Cyanoacrylate fixation can support proactive vascular access care, offering a safe and feasible option to prevent complications rather than reacting to them after they occur. No adverse local effects were observed with cyanoacrylate adhesive, suggesting compatibility with neonatal skin and alignment with the Right Patient, Right Device, and Right Care principles within the 7 Rights of Neonatal Vascular Access.
Our Most Popular Resources
Maternal RSV Vaccination, Infant Nirsevimab, or Both
Maternal RSV vaccination and infant nirsevimab immunization, administered either alone or sequentially, were safe and provided high RSV-A and -B nAb titers in infants that persisted through 3 months after delivery. While most infants will not need to receive both products to be protected, our results suggest that maternal RSV vaccination and infant nirsevimab immunization may be safely sequentially administered.
Our Most Popular Resources
FDA Approves First Single-Dose Generic Treatment for Influenza
FDA approved the first generic single-dose baloxavir marboxil tablet for influenza in patients aged 5 years and above, ahead of the 20262027 flu season. Approved for both acute uncomplicated influenza treatment (within 48 hours of symptom onset) and post-exposure prophylaxis, this milestone may improve access, affordability, and ease of antiviral use in clinical practice.
Our Most Popular Resources
Specialty: